Are you Dr. Lauring?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 50 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Crb I RM 146
1650 Orleans St
Baltimore, MD 21287Phone+1 410-502-8164Fax+1 410-614-4073- Is this information wrong?
Summary
- Dr. Josh Lauring, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland. He is an Assistant Professor of Oncology at Johns Hopkins University School of Medicine.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
- Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
- Johns Hopkins University School of MedicineClass of 2000
Certifications & Licensure
- MD State Medical License 2003 - 2024
Publications & Presentations
PubMed
- 7 citationsActive growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.Gemma A Wilson, Karla Vuina, Georgina Sava, Caroline Huard, Leticia Meneguello, Jasmin Coulombe-Huntington, Thierry Bertomeu, Rory J Maizels, Josh Lauring, Janos Krist...> ;Molecular Cell. 2023 Nov 16
- 2 citationsPhase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.Tamanna Haque, Felix López Cadenas, Blanca Xicoy, Ana Alfonso-Pierola, Uwe Platzbecker, Irit Avivi, Andrew M Brunner, Jöerg Chromik, Daniel Morillo, Manish R Patel, Jo...> ;Leukemia Research. 2023 Nov 1
- 6 citationsPhase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron R Hansen, Bernard Doger, Vladimir Galvao, Laur...> ;Clinical Cancer Research. 2023 Sep 15
- Join now to see all
Press Mentions
- Hopkins Researcher Describes Evolving Challenges of Targeting PI3K in Breast CancerMarch 12th, 2015
Professional Memberships
- Member